Comparative Pharmacology
Head-to-head clinical analysis: CEFPIRAMIDE SODIUM versus RESPORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFPIRAMIDE SODIUM versus RESPORAL.
CEFPIRAMIDE SODIUM vs RESPORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefpiramide sodium is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
RESPORAL contains theophylline, a methylxanthine that inhibits phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cAMP and cGMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation and anti-inflammatory effects.
1-2 g IV every 12 hours; maximum 8 g/day
2 mg orally twice daily
None Documented
None Documented
4-5 hours in normal renal function; prolonged to 12-20 hours in severe renal impairment (CrCl < 20 mL/min)
Terminal half-life is 12 hours (range 10-14 h), supporting twice-daily dosing in most patients.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: 10-20%
Renal excretion accounts for 70% of elimination (30% unchanged), biliary/fecal 20%, and 10% metabolized.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic